1. 1841PRefining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability. (23rd October 2018) Authors: Matos Garcia, I; García Ruiz, A; Martin-Liberal, J; Hierro, C; Ochoa De Olza Amat, M; Viaplana, C; Mur, G; Vieito Villar, M; Brana, I; Azaro, A; Perez, C; Rodriguez Freixinos, V; Argiles, G; Oliveira, M; Felip Font, E; Muñoz-Couselo, E; Tabernero, J; Dienstmann, R; Garralda, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 968POutcomes of ovarian clear cell carcinoma (OCCC) of the Vall d'Hebron Hospital/Vall d'Hebron Institute of Oncology (VHIO). (23rd October 2018) Authors: Amair Pinedo, F; Fariñas-Madrid, L; Rodriguez Freixinos, V; Ros Montañá, F J; Villacampa, G; Dienstmann, R; Oaknin, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 988PBenefit from subsequent conventional cytotoxic chemotherapy (CTx) to immunotherapy (IT) in patients (pts) with gynaecological malignancies (GM). (23rd October 2018) Authors: Ros Montañá, F J; Rodriguez Freixinos, V; Fariñas Madrid, L; Amair Pinedo, F; Ruiz-Pace, F; Garralda, E; Dienstmann, R; Oaknin, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗